“Multiple Myeloma & Lymphoma” was moderated by Li Watsek and featured Kevin Xie, CFO of Gracell Biotechnologies and Richard Vincent, CFO of Oncternal Therapeutics.

• Gracell noted its rich pipeline of opportunity, including five pipelines that have clinical data published. It also highlighted its FasTCAR platform that has next-day manufacturing.

• Oncternal focused on its investigational product candidate zilovertamab for mantle cell lymphoma, noting its unique but validated target ROR1. It also touched on the development of a ROR1 CAR-T to address the unmet need in efficacy for this indication.

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare